EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Intranasal administration of octavalent next-generation influenza vaccine elicits protective immune responses against seasonal and pre-pandemic viruses

Naoko Uno iD, Thomas Ebensen, Carlos A Guzman, Ted M Ross iD

Journal of Virology · 2024

DOI: 10.1128/jvi.00354-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Virology, 2024. Verfasst von Naoko Uno und 3 weiteren Autor:innen. Beteiligte Einrichtung: Center for Vaccines and Immunology, University of Georgia, Athens, Georgia, USA. Hauptthemen laut MEDLINE: Influenza Vaccines, Administration, Intranasal, Ferrets, Antibodies, Viral. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union, Georgia Research Alliance (GRA), Government of India.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Development of next-generation influenza virus vaccines is crucial to improve protection against circulating and emerging viruses. Current vaccine formulations have to be updated annually due to mutations in seasonal strains and do not offer protection against strains with pandemic potential. Computationally optimized broadly reactive antigen (COBRA) methodology has been utilized by our group to generate broadly reactive immunogens for individual influenza subtypes, which elicit protective immune responses against a broad range of strains over numerous seasons. Octavalent mixtures of COBRA hemagglutinin (HA) (H1, H2, H3, H5, H7, and influenza B virus) plus neuraminidase (NA) (N1 and N2) recombinant proteins mixed with c-di-AMP adjuvant were administered intranasally to naive or pre-immune ferrets in prime-boost fashion. Four weeks after final vaccination, collected sera were analyzed for breadth of antibody response, and the animals were challenged with seasonal or pre-pandemic strains. The octavalent COBRA vaccine elicited antibodies that recognized a broad panel of strains representing different subtypes, and these vaccinated animals were protected against influenza virus challenges. Overall, this study demonstrated that the mixture of eight COBRA HA/NA proteins mixed with an intranasal adjuvant is a promising candidate for a universal influenza vaccine. IMPORTANCE Influenza is a respiratory virus which infects around a billion people globally every year, with millions experiencing severe illness. Commercial vaccine efficacy varies year to year and can be low due to mismatch of circulating virus strains. Thus, the formulation of current vaccines has to be adapted accordingly every year. The development of a broadly reactive influenza vaccine would lessen the global economic and public health burden caused by the different types of influenza viruses. The significance of our research is producing a promising universal vaccine candidate which provides protection against a wider range of virus strains over a wider range of time.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza VaccinesAdministration, IntranasalFerretsAntibodies, ViralOrthomyxoviridae InfectionsHemagglutinin Glycoproteins, Influenza VirusAnimalsNeuraminidaseSeasonsAdjuvants, ImmunologicVaccinationInfluenza, HumanHumansFemaleCross ProtectionPandemics

Stichwörter der Autor:innen

COBRASting agonistferretinfluenzaintranasalmicemultivalentvaccine

Substanzen

Influenza VaccinesAntibodies, ViralHemagglutinin Glycoproteins, Influenza VirusNeuraminidaseAdjuvants, Immunologic

Autor:innen und Institutionen

  • Center for Vaccines and Immunology, University of Georgia, Athens, Georgia, USA.
  • Department of Infection Biology, Lehner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
  • Florida Research and Innovation Center, Cleveland Clinic, Port Saint Lucie, Florida, USA.
  • Department of Infectious Diseases, University of Georgia, Athens, Georgia, USA.

ORCID-Profile: Naoko Uno, Ted M Ross

Förderung

  • European Union
  • Georgia Research Alliance (GRA)
  • Government of India

Zitieren

APA

Uno, N., Ebensen, T., Guzman, C. A., & Ross, T. M. (2024). Intranasal administration of octavalent next-generation influenza vaccine elicits protective immune responses against seasonal and pre-pandemic viruses. Journal of Virology. https://doi.org/10.1128/jvi.00354-24

Vancouver

Uno N, Ebensen T, Guzman CA, Ross TM. Intranasal administration of octavalent next-generation influenza vaccine elicits protective immune responses against seasonal and pre-pandemic viruses. Journal of Virology. 2024. doi:10.1128/jvi.00354-24

BibTeX
@article{Uno2024,
  author = {Uno, Naoko and Ebensen, Thomas and Guzman, Carlos A and Ross, Ted M},
  title = {Intranasal administration of octavalent next-generation influenza vaccine elicits protective immune responses against seasonal and pre-pandemic viruses},
  journal = {Journal of Virology},
  year = {2024},
  doi = {10.1128/jvi.00354-24}
}
Kostenlos starten →